再论干细胞疗法，多个适应症迎来关键进展，建议关注九芝堂和中源协和等

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [6]. Core Insights - The report emphasizes the significant progress in stem cell therapy across multiple indications, suggesting a focus on companies like Jiuzhitang and Zhongyuan Qihe [3][5]. - The investment strategy is centered around three main themes: innovation, recovery, and policy support, with a strong emphasis on innovative drugs as the most clear long-term trend in the pharmaceutical sector [5]. Summary by Sections 1. Investment Focus on Pharmaceutical Combinations - The recommended investment combination outperformed the pharmaceutical index by 2.8 percentage points and the broader market by 3.1 percentage points last week [12]. 2. Stem Cell Therapy: Policy and Progress - China's regenerative medicine has reached a world-leading level, with clear industry policies marking a golden development period for stem cell therapy [17]. - Multiple indications are seeing critical advancements, with expectations for key data releases this year [17]. - The first domestically approved stem cell therapy was launched in January 2025, marking a historic turning point for the industry [6][17]. 3. Weekly Market Review and Hotspot Tracking (May 12-16, 2025) - The CITIC Pharmaceutical Index rose by 1.4%, outperforming the CSI 300 Index by 0.3 percentage points, ranking 10th among CITIC's primary industry classifications [61]. - The pharmaceutical sub-sectors showed positive performance, with chemical raw materials up by 2.79% and traditional Chinese medicine up by 2.01% [64].